Significance of TLR4/MyD88 expression in breast cancer.
OBJECTIVE
To investigate the expression of TLR4/MyD88 in breast cancer, and explore the relationship between their expression and breast cancer tumor growth and invasion.


METHODS
We examined the protein expression of TLR4 and MyD88 in 60 cases of histologically confirmed breast cancer. The relationship of their protein expressions with clinical features including age at diagnosis, tumor size and stage, lymph node metastasis and distant metastasis were analyzed.


RESULTS
The IHC results showed that TLR4 and MyD88 were expressed in 63.3% (38/60) and 58.3% (35/60) of malignant breast tumors respectively. TLR4 expression in breast cancer were significantly higher than in fibroadenoma (n = 4, 20.0%) and adjacent normal tissues (n = 2, 10.0%) (P < 0.001). MyD88 expression in breast cancer were also significantly higher than in fibroadenoma (n = 4, 20.0%) and adjacent normal tissue (n = 3, 15.0%) (P < 0.001). The gene expressions of TLR4 and MyD88 were significantly higher in breast cancer than in fibroadenoma and adjacent normal tissues (P < 0.05). The protein expressions of TLR4 and MyD88 were also significantly associated with poor clinical features (P < 0.05).


CONCLUSIONS
TLR4 and MyD88 expression might be associated with breast cancer growth and regional and distant metastases.
Department of Thyroid and Breast Surgery, First Affiliated Hospital of Fujian Medical University China.
Xiangjin
X
Chen
Fujian Medical University Graduate School China.
Feng
F
Zhao
Department of Thyroid and Breast Surgery, First Affiliated Hospital of Fujian Medical University China.
Huihao
H
Zhang
Department of Thyroid and Breast Surgery, First Affiliated Hospital of Fujian Medical University China.
Youzhi
Y
Zhu
Department of Thyroid and Breast Surgery, First Affiliated Hospital of Fujian Medical University China.
Kunlin
K
Wu
Fujian Medical University Graduate School China.
Guozheng
G
Tan
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D001943:Breast Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016022:Case-Control Studies; D005260:Female; D018226:Fibroadenoma / Q000737:chemistry* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D053594:Myeloid Differentiation Factor 88 / Q000032:analysis* / Q000235:genetics; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D051197:Toll-Like Receptor 4 / Q000032:analysis* / Q000235:genetics; D016896:Treatment Outcome; D047368:Tumor Burden; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4
Breast cancer; MyD88; TLR4